Solid-tumour CAR-T · Pre-clinical

Effective outpatient
CAR‑T for solid tumours.

Durable, targeted, low-toxicity — engineered to reach the patients today’s therapies can’t.

Seed stage mCRC · 2L+ GALWAY X RINN
Explore the platform The four barriers
Scroll
The moat / 01

Four barriers have kept
CAR-T out of solid tumours.

Each has its own well-documented failure mode. Gaisce engineers an answer to all four — trafficking, infiltration, persistence and safety — inside a single cell.

  1. B-01

    Trafficking

    Failure mode Engineered cells never reach the tumour bed.

    Gaisce A navigation system that directs the cell toward the tumour.

  2. B-02

    Infiltration

    Failure mode The hostile microenvironment locks cells out.

    Gaisce A solid-tumour breaker that gets inside and survives entry.

  3. B-03

    Persistence

    Failure mode Cells exhaust and disappear before the job is done.

    Gaisce Intrinsic durability that sustains activity over time.

  4. B-04

    Safety

    Failure mode Toxicity forces costly inpatient management.

    Gaisce Autonomous safety designed for the outpatient setting.

The platform / 02

One engineered cell.
Three systems.

We don’t bolt on a single fix. The platform integrates manufacturing, navigation and safety into one cell — each system addressing a different barrier, together making outpatient solid-tumour therapy feasible.

Hover a system to locate it in the cell

S-01

BacPac™

The launch vehicle

Non-viral, large-payload manufacturing — the vehicle that carries the full engineered package into the cell.

Biologic economics, not service economics.
S-02

STNAV™

The solid-tumour breaker

Homing, infiltration and survival, integrated into one navigation system that finds the tumour and gets inside.

A tumour-agnostic homing engine.
S-03

Stayble‑T™

The market unlock

Autonomous safety and intrinsic durability — the combination that moves treatment toward the outpatient setting.

Engineered to be outpatient-ready.
In motion / 03

Find the tumour.
Get inside. Stay.

An illustrative time-lapse of the behaviour the platform is designed for: engineered cells locate a cluster of tumour cells, engage it, and remain active. A rendering, not experimental data.

Lead construct / 04

A receptor chosen for breadth.
A signal chosen for tolerability.

Our lead construct is tumour-agnostic; our first target indication will be second-line and later metastatic colorectal cancer. It pairs broad, multi-ligand recognition with a signalling architecture selected for a cleaner tolerability profile than first-generation designs.

These are engineering decisions, not claims — each one made against a named failure mode, and each one carried forward only when the data clears our bar.

How we de-risk
Credibility / 05

Tier-1 science incubated inside
Tier-1 academic infrastructure.

€40M Integrated in Government backed Rinn Research Centre for Advanced Therapies
4/7 Commercial CAR-T delivered by our team
0 Barriers solved in one cell
1 Construct carrying the platform

We are not learning cell
therapy on this asset.

Building the navigation system for solid-tumour cell therapy — measured, evidence-grounded, and engineered end to end.

Investor enquiries Our approach

We are supported by